Targeting FGFR pathway in breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Breast cancer subtypes have been molecularly profiled, leading to improved personalized therapies and patient outcomes.
• Targeted therapies, particularly those inhibiting kinase gene alterations, have transformed cancer treatment.
• Fibroblast growth factors and their receptors (FGFRs) are crucial in physiological processes and cancer progression.

Purpose of the Study:

• To summarize molecular alterations of FGFRs in breast cancer.
• To review preclinical and clinical data on FGFR inhibitors for breast cancer.
• To discuss future clinical development opportunities for FGFR-targeted agents.

Main Methods:

• Literature review of preclinical studies.
• Analysis of clinical trial data for FGFR inhibitors in breast cancer.
• Synthesis of information on FGFR molecular alterations.

Main Results:

• FGFRs are implicated in breast cancer cell proliferation, survival, differentiation, migration, and apoptosis.
• Several FGFR alterations are actionable drug targets.
• Preclinical and clinical data demonstrate the potential of FGFR inhibitors.

Conclusions:

• FGFR alterations represent a significant area for targeted breast cancer therapy.
• FGFR inhibitors show promise for treating specific breast cancer subtypes.
• Further clinical development of FGFR inhibitors may offer new treatment avenues for breast cancer patients.